% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Srivastava:602307,
      author       = {Srivastava, Sukrit and Verma, Sonia and Kamthania, Mohit
                      and Saxena, Ajay Kumar and Pandey, Kailash C. and Pande,
                      Veena and Kolbe, Michael},
      title        = {{E}xploring the structural basis to develop efficient
                      multi-epitope vaccines displaying interaction with {HLA} and
                      {TAP} and {TLR}3 molecules to prevent {NIPAH} infection, a
                      global threat to human health},
      journal      = {PLOS ONE},
      volume       = {18},
      number       = {3},
      issn         = {1932-6203},
      address      = {San Francisco, California, US},
      publisher    = {PLOS},
      reportid     = {PUBDB-2024-00582},
      pages        = {e0282580 -},
      year         = {2023},
      abstract     = {Nipah virus (NiV) is an emerging zoonotic virus that caused
                      several serious outbreaks in the south asian region with
                      high mortality rates ranging from 40 to $90\%$ since 2001.
                      NiV infection causes lethal encephalitis and respiratory
                      disease with the symptom of endothelial cell-cell fusion. No
                      specific and effective vaccine has yet been reported against
                      NiV. To address the urgent need for a specific and effective
                      vaccine against NiV infection, in the present study, we have
                      designed two Multi-Epitope Vaccines (MEVs) composed of 33
                      Cytotoxic T lymphocyte (CTL) epitopes and 38 Helper T
                      lymphocyte (HTL) epitopes. Out of those CTL and HTL combined
                      71 epitopes, 61 novel epitopes targeting nine different NiV
                      proteins were not used before for vaccine design. Codon
                      optimization for the cDNA of both the designed MEVs might
                      ensure high expression potential in the human cell line as
                      stable proteins. Both MEVs carry potential B cell linear
                      epitope overlapping regions, B cell discontinuous epitopes
                      as well as IFN-γ inducing epitopes. Additional criteria
                      such as sequence consensus amongst CTL, HTL and B Cell
                      epitopes was implemented for the design of final constructs
                      constituting MEVs. Hence, the designed MEVs carry the
                      potential to elicit cell-mediated as well as humoral immune
                      response. Selected overlapping CTL and HTL epitopes were
                      validated for their stable molecular interactions with HLA
                      class I and II alleles and in case of CTL epitopes with
                      human Transporter Associated with antigen Processing (TAP)
                      cavity. The structure based epitope cross validation for
                      interaction with TAP cavity was used as another criteria
                      choosing final epitopes for NiV MEVs. Finally, human
                      Beta-defensin 2 and Beta-defensin 3 were used as adjuvants
                      to enhance the immune response of both the MEVs. Molecular
                      dynamics simulation studies of MEVs-TLR3 ectodomain (Human
                      Toll-Like Receptor 3) complex indicated the stable molecular
                      interaction. We conclude that the MEVs designed and in
                      silico validated here could be highly potential vaccine
                      candidates to combat NiV infections, with great
                      effectiveness, high specificity and large human population
                      coverage worldwide.},
      cin          = {CSSB-HZI-MK},
      ddc          = {610},
      cid          = {I:(DE-H253)CSSB-HZI-MK-20210520},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      experiment   = {EXP:(DE-MLZ)NOSPEC-20140101},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36920996},
      UT           = {WOS:000954452200063},
      doi          = {10.1371/journal.pone.0282580},
      url          = {https://bib-pubdb1.desy.de/record/602307},
}